OSA Linked to Higher Cardiovascular Risk
Analysis based on 6 articles · First reported Apr 03, 2026 · Last updated Apr 06, 2026
The study's findings, linking obstructive sleep apnea to higher cardiovascular risks, could increase demand for diagnostic tools and treatments for both sleep apnea and obesity. This may positively impact pharmaceutical companies like Eli Lilly and Company involved in related research and development, as well as the broader healthcare industry.
A new international study, a collaboration between Imperial College Health Partners, Imperial College Healthcare NHS Trust, and Eli Lilly and Company, has found that individuals with obstructive sleep apnea (OSA) have a 71% higher risk of cardiovascular events or death from any cause compared to those without OSA. The research, co-authored by Heather Fitzke, highlights that this risk is particularly elevated among people with obesity. The study, which analyzed electronic health records from 2.9 million residents, is considered the largest matched case-control study of OSA outside the United_States. The findings underscore the urgent need for effective obesity management, early screening, and timely diagnosis of sleep apnea. The results will be presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey, from May 12-15.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard